Evidence map›Paper›PMID 37115755›Full record

ArticlePloS one2023

IL-17 cytokines preferentially act on naïve CD4+ T cells with the IL-17AF heterodimer inducing the greatest functional changes.

Michael P Crawford, Nicholas Borcherding, Nitin J Karandikar

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michael P CrawfordDepartment of Pathology, University of Iowa Health Care, Iowa City, Iowa, United States of America.
Nicholas BorcherdingDepartment of Pathology, University of Iowa Health Care, Iowa City, Iowa, United States of America.
Nitin J KarandikarDepartment of Pathology, University of Iowa Health Care, Iowa City, Iowa, United States of America.ORCID 0000-0002-6867-6950
University of Iowa Health Care · US

Funding

Immune Dysregulation During Multiple Sclerosis RelapseR01AI121567 · NIAID · UNIVERSITY OF IOWA · PI KARANDIKAR, NITIN J · 2016 to 2020
$3.8M
Effector-Regulator Immune Interactions During Autoimmune Demyelinating DiseaseI01CX002319 · VA · IOWA CITY VA MEDICAL CENTER · PI NITIN J KARANDIKAR · 2022 to 2026
–
CSRD VA I01 CX002319NIAID NIH HHS R01 AI121567
6 · The paper itself

Abstract

CD4+ T-helper 17 (Th17) T cells are a key population in protective immunity during infection and in self-tolerance/autoimmunity. Through the secretion of IL-17, Th17 cells act in promotion of inflammation and are thus a major potential therapeutic target in autoimmune disorders. Recent reports have brought to light that the IL-17 family cytokines, IL-17A, IL-17F and IL-17AF, can directly act on CD4+ T-cells, both in murine and human systems, inducing functional changes in these cells. Here we show that this action is preferentially targeted toward naïve, but not memory, CD4+ T-cells. Naïve cells showed transcriptome changes as early as 48 hours post-IL-17 exposure, whereas memory cells remained unaffected as late as 7 days. These functional differences occurred despite similar IL-17 receptor expression on these subsets and were maintained in co-culture/transwell systems, with each subset maintaining its functional response to IL-17. Importantly, there were differences in downstream transcriptional signaling by the three IL-17 cytokines, with the IL-17AF heterodimer conferring both the greatest transcriptional change and most altered functional consequences. Detailed transcriptome analysis provides important insights into the genes and pathways that are modulated as a result of IL-17-mediated signaling and may serve as targets of future therapies.

Indexed as

Autoimmune DiseasesInterleukin-17AnimalsCD4-Positive T-LymphocytesCytokinesHumansInflammationMiceTh17 CellsCytokinesInterleukin-17

Identifiers

PMID37115755
PMCPMC10146571
OpenAlexW4367309386

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.